Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome
NCT07218653Phase 1Not yet recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2026
- Primary completion
- Jul 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of indomethacin in metabolic syndrome (2 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Cerebral Blood Flow at 6 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
indomethacin
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT07218653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218653.